Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

50.0%

1 terminated/withdrawn out of 2 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Early Phase 1
1(50.0%)
Phase 2
1(50.0%)
2Total
Early Phase 1(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (2)

Showing 2 of 2 trials
NCT04781088Phase 2Active Not Recruiting

Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Role: lead

NCT04906382Early Phase 1Terminated

Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer

Role: lead

All 2 trials loaded